Overview of systematic reviews of non-pharmacological interventions in women with polycystic ovary syndrome

Human Reproduction Update

Volumn 25, Issue 2, 2019, Pages 243-256

  Pundir, Jyotsna ^a   Charles, David ^b   Sabatini, Luca ^a   Hiam, Danielle ^c   Jitpiriyaroj, Sonia ^d   Teede, Helena ^d   Coomarasamy, Arri ^e   Moran, Lisa ^d   Thangaratinam, Shakila ^f  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c VICTORIA UNIVERSITY   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Acupuncture; Chinese herbal medicine; Inositol; Lifestyle intervention; N acetylcysteine; Non pharmacological interventions; PCOS

Indexed keywords

ACETYLCYSTEINE; ANDROGEN; CLOMIFENE CITRATE; GLUCOSE; INOSITOL; INSULIN; METFORMIN; OMEGA 3 FATTY ACID; PLACEBO; TESTOSTERONE; VITAMIN D;

ACUPUNCTURE; ARTICLE; BIRTH RATE; BODY MASS; DIET; DIET SUPPLEMENTATION; FEMALE FERTILITY; GLUCOSE BLOOD LEVEL; HERBAL MEDICINE; HIRSUTISM; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN BLOOD LEVEL; MENSTRUAL CYCLE; OVARY POLYCYSTIC DISEASE; OVULATION; PHYSICAL ACTIVITY; PREGNANCY RATE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; ALTERNATIVE MEDICINE; DIETARY SUPPLEMENT; FEMALE; INFERTILITY; LIFESTYLE; METABOLISM; MULTIPLE PREGNANCY; OVULATION INDUCTION; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; PROCEDURES;

ACETYLCYSTEINE; COMPLEMENTARY THERAPIES; DIETARY SUPPLEMENTS; FEMALE; HUMANS; INFERTILITY; INOSITOL; LIFE STYLE; OVULATION; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY RATE; PREGNANCY, MULTIPLE; SYSTEMATIC REVIEWS AS TOPIC;

EID: 85062172870     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmy045     Document Type: Article

References (44)

1. Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab 2005;90:4650-4658.
2. Baillargeon JP, Iuorno MJ, Apridonidze T, Nestler JE. Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women with polycystic ovary syndrome. Metab Syndr Relat Disord 2010;8:127-136.
3. Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C, Jacobs HS. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995;10:2107-2111.
4. Balen AH, Morley LC, Misso M, Franks S, Legro RS, Wijeyaratne CN, Stener-Victorin E, Fauser BC, Norman RJ, Teede H. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update 2016;22:687-708.
5. Boots C, Stephenson MD. Does obesity increase the risk of miscarriage in spontaneous conception: a systematic review. Semin Reprod Med 2011;29:507-513.
6. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 2016;31:2841-2855.
7. Brusco GF, Mariani M. Inositol: effects on oocyte quality in patients undergoing ICSI. An open study. Eur Rev Med Pharmacol Sci 2013;17:3095-3102.
8. Cooney LG, Lee I, Sammel MD, Dokras A. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 2017;32:1075-1091.
9. D'Anna R, Di Benedetto A, Scilipoti A, Santamaria A, Interdonato ML, Petrella E, Neri I, Pintaudi B, Corrado F, Facchinetti F. Myo-inositol supplementation for prevention of gestational diabetes in obese pregnant women: a randomized controlled trial. Obstet Gynecol 2015;126:310-315.
10. Domecq JP, Prutsky G, Mullan RJ, Hazem A, Sundaresh V, Elamin MB, Phung OJ, Wang A, Hoeger K, Pasquali R et al. Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis. J Clin Endocrinol Metab 2013;98:4655-4663.
11. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN, PCOS/ Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:48-53.
12. Fang F, Ni K, Cai Y, Shang J, Zhang X, Xiong C. Effect of vitamin D supplementation on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Complement Ther Clin Pract 2017;26:53-60.
13. Glueck CJ, Dharashivkar S, Wang P, Zhu B, Gartside PS, Tracy T, Sieve L. Obesity and extreme obesity, manifest by ages 20-24 years, continuing through 32-41 years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy. Eur J Obstet Gynecol Reprod Biol 2005;122:206-212.
14. Goodman NF, Bledsoe MB, Cobin RH, Futterweit W, Goldzieher JW, Petak SM, Smith KD, Steinberger E, American Association of Clinical Endocrinologists Hyperandrogenic Disorders Task Force. American Association of Clinical Endocrinologists medical guidelines for the clinical practice for the diagnosis and treatment of hyperandrogenic disorders. Endocr Pract 2001;7:120-134.
15. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ, GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br Med J 2008;336:924-926.
16. Haqq L, McFarlane J, Dieberg G, Smart N. Effect of lifestyle intervention on the reproductive endocrine profile in women with polycystic ovarian syndrome: a systematic review and meta-analysis. Endocr Connect 2014;3:36-46.
17. Haqq L, McFarlane J, Dieberg G, Smart N. The effect of lifestyle intervention on body composition, glycemic control, and cardiorespiratory fitness in polycystic ovarian syndrome: a systematic review and meta-analysis. Int J Sport Nutr Exerc Metab 2015;25:533-540.
18. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004; 18:671-683.
19. Jo J, Lee YJ, Lee H. Acupuncture for polycystic ovarian syndrome: a systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e7066.
20. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, Franks S. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992;36: 105-111.
21. Legro RS, Dodson WC, Kris-Etherton PM, Kunselman AR, Stetter CM, Williams NI, Gnatuk CL, Estes SJ, Fleming J, Allison KC et al. Randomized controlled trial of preconception interventions in infertile women with polycystic ovary syndrome. J Clin Endocrinol Metab 2015;100:4048-4058.
22. Lim CE, Ng RW, Xu K, Cheng NC, Xue CC, Liu JP, Chen N. Acupuncture for polycystic ovarian syndrome. Cochrane Database Syst Rev 2016;5:CD007689.
23. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010;25:544-551.
24. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Br Med J 2009;339:b2535.
25. Moran LJ, Brinkworth G, Noakes M, Norman RJ. Effects of lifestyle modification in polycystic ovarian syndrome. Reprod Biomed Online 2006;12:569-578.
26. Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2011;7:CD007506.
27. Nasr A. Effect of N-acetyl-cysteine after ovarian drilling in clomiphene citrateresistant PCOS women: a pilot study. Reprod Biomed Online 2010;20:403-409.
28. Papaleo E, Unfer V, Baillargeon JP, Chiu TT. Contribution of myo-inositol to reproduction. Eur J Obstet Gynecol Reprod Biol 2009;147:120-123.
29. Pundir J, Psaroudakis D, Savnur P, Bhide P, Sabatini L, Teede H, Coomarasamy A, Thangaratinam S. Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. BJOG 2017;125:299-308.
30. Qin JZ, Pang LH, Li MJ, Fan XJ, Huang RD, Chen HY. Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol 2013;11:56.
31. Qu F, Wu Y, Hu X-Y, Barry JA, Zhou J, Wang F-F, Ye Y-H, Zhang R, Han S-P, Han J-S et al. The effects of acupuncture on polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Integr Med 2016;1:12-18.
32. Ravanos K, Monastra G, Pavlidou T, Goudakou M, Prapas N. Can high levels of Dchiro-inositol in follicular fluid exert detrimental effects on blastocyst quality? Eur Rev Med Pharmacol Sci 2017;21:5491-5498.
33. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25; Hum Reprod. 2004;19 (1):41-7.
34. Sadeghi A, Djafarian K, Mohammadi H, Shab-Bidar S. Effect of omega-3 fatty acids supplementation on insulin resistance in women with polycystic ovary syndrome: Meta-analysis of randomized controlled trials. Diabetes Metab Syndr 2017;11: 157-162.
35. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, Porter AC, Tugwell P, Moher D, Bouter LM. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007;7:10.
36. Silva V, Grande AJ, Carvalho AP, Martimbianco AL, Riera R. Overview of systematic reviews-a new type of study. Part II. Sao Paulo Med J 2015;133:206-217.
37. Smith V, Devane D, Begley CM, Clarke M. Methodology in conducting a systematic review of systematic reviews of healthcare interventions. BMC Med Res Methodol 2011;11:15.
38. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010;8:41.
39. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ, International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod 2018;33:1602-1618.
40. Teede HJ, Misso ML, Deeks AA, Moran LJ, Stuckey BG, Wong JL, Norman RJ, Costello MF, Guideline Development Groups. Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Med J Aust 2011;195:S65-S112.
41. Thakker D, Raval A, Patel I, Walia R. N-Acetylcysteine for polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled clinical trials. Obstet Gynecol Int 2015;2015:817849.
42. Toulis KA, Goulis DG, Kolibianakis EM, Venetis CA, Tarlatzis BC, Papadimas I. Risk of gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Fertil Steril 2009;92:667-677.
43. Zawadski JK, Dunaif A Diagnostic Criteria for Polycystic Ovary Syndrome: Towards a Rational Approach. Boston: Blackwell Scientific Publications 1992; 377-384.
44. Zhou K, Zhang J, Xu L, Wu T, Lim CE. Chinese herbal medicine for subfertile women with polycystic ovarian syndrome. Cochrane Database Syst Rev 2016;10: CD007535.